Sourcing 4-Nitro-2,3-Lutidine-N-Oxide: Solvent Swelling Filtration Hurdles
Technical Specifications and Purity Grades for 4-Nitro-2,3-lutidine-N-oxide in API Synthesis
In the synthesis of Lansoprazole and related proton pump inhibitors, 4-Nitro-2,3-lutidine-N-oxide (CAS 37699-43-7) serves as a critical pyridine N-oxide intermediate. This compound, also referred to as 2,3-Dimethyl-4-nitropyridine N-Oxide or 4-Nitro-2,3-dimethylpyridine N-oxide, is typically supplied at purities of 97% or ≥98% (HPLC). However, for pharmaceutical applications, the difference between a generic 97% grade and a tightly controlled pharmaceutical grade can be significant. At NINGBO INNO PHARMCHEM, our standard offering targets ≥98% purity with individual impurity profiles rigorously controlled to meet API intermediate requirements. The table below compares typical purity grades available in the market and their suitability for different synthesis stages.
| Grade | Purity (HPLC) | Typical Application | Key Impurity Limits |
|---|---|---|---|
| Technical | ≥97% | R&D, pilot studies | Single impurity ≤1.0% |
| Pharmaceutical Intermediate | ≥98% | API synthesis (Lansoprazole) | Single impurity ≤0.5%, total impurities ≤1.5% |
| High Purity | ≥99% | Late-stage API, critical steps | Single impurity ≤0.3%, total impurities ≤1.0% |
When evaluating a Lutidine N-oxide derivative for your process, it is essential to look beyond the headline purity. Trace impurities such as unreacted 2,3-lutidine, over-oxidized byproducts, or positional isomers can impact downstream reaction yields and final API purity. Our batch-specific COA provides detailed impurity profiles, ensuring you have the data needed for process validation. For a deeper dive into the specifications that matter for pharmaceutical synthesis, refer to our detailed analysis on pharmaceutical grade COA specs.
Decoding the Certificate of Analysis: Critical Parameters and Trace Solvent Profiles
A Certificate of Analysis (COA) for 4-Nitro-2,3-lutidine-N-oxide is more than a purity statement; it is a fingerprint of the manufacturing process. Key parameters include assay (HPLC), melting point (94–98°C), water content (Karl Fischer), and residue on ignition. However, for process engineers, the trace solvent profile is often the deciding factor. Residual solvents from the synthesis route—typically involving nitration of 2,3-lutidine-N-oxide—can include acetic acid, methanol, or chlorinated solvents. These must be controlled to ICH Q3C limits if the intermediate is used in late-stage API synthesis. Our COA includes a detailed residual solvent analysis by GC, ensuring compliance with pharmacopeial standards. Additionally, the appearance (pale yellow to yellow crystalline powder) can indicate purity; darker hues may suggest degradation or impurity carryover. For those tracking global pricing trends alongside quality, our bulk price analysis for 2026 provides market context.
Bulk Packaging and Logistics: IBCs, 210L Drums, and Solvent Swelling Filtration Challenges
Procurement managers sourcing 4-Nitro-2,3-lutidine-N-oxide in bulk must navigate packaging and logistics with precision. Standard packaging options include 25kg fiber drums with PE liners, 210L steel drums, and for large-scale orders, intermediate bulk containers (IBCs). The compound is classified as a combustible solid (Storage Class 11) and requires storage in a sealed, dry environment at room temperature. However, a less-discussed challenge is solvent swelling filtration. During synthesis, if the product is isolated by filtration from a solvent system, residual solvents can cause the filter cake to swell, leading to blinding of filter media and extended processing times. This is particularly relevant when the product is supplied as a wet cake or when repulping is required. Our team has field experience in optimizing filtration conditions—such as controlled vacuum levels and solvent selection—to mitigate these issues. We recommend discussing your specific filtration setup with our technical team to ensure seamless integration into your process.
Field Notes on Non-Standard Behavior: Viscosity Shifts and Crystallization in Sub-Zero Handling
Beyond standard specifications, hands-on experience reveals that 4-Nitro-2,3-lutidine-N-oxide exhibits subtle but impactful behaviors under certain conditions. One such edge case is the viscosity shift of its solutions at sub-zero temperatures. While the compound itself is a solid, process streams containing this nitro-lutidine oxide in solvents like methanol or chloroform can show increased viscosity near 0°C, affecting pumpability and mixing. This is not a published parameter but a field observation that can influence plant design in cold climates. Another practical note concerns crystallization: when recrystallizing from methanol, rapid cooling can lead to a fine, slow-filtering powder, whereas controlled cooling yields larger, more easily handled crystals. These insights come from years of manufacturing this pyridine N-oxide intermediate and are shared to help process engineers avoid common pitfalls. For precise handling recommendations, please refer to the batch-specific COA.
Sourcing Strategy: Evaluating 4-Nitro-2,3-lutidine-N-oxide as a Drop-in Replacement for Lansoprazole Intermediates
For pharmaceutical manufacturers, qualifying a new source of 4-Nitro-2,3-lutidine-N-oxide often means seeking a drop-in replacement that matches the performance of established suppliers without requalification headaches. At NINGBO INNO PHARMCHEM, we position our product as a seamless alternative, offering identical technical parameters—purity, impurity profile, and physical form—while delivering cost efficiencies and supply chain reliability. Our high-purity Lansoprazole intermediate is manufactured under strict quality control, and we provide comprehensive documentation to support regulatory filings. By focusing on consistent quality and transparent communication, we enable R&D managers to switch sources with confidence, reducing validation time and risk.
Frequently Asked Questions
What is the minimum order quantity (MOQ) for 4-Nitro-2,3-lutidine-N-oxide?
Our standard MOQ is 1 kg for sample evaluation and 25 kg for commercial orders. Custom packaging and smaller quantities can be arranged for R&D purposes.
How do you ensure batch-to-batch consistency for pharmaceutical synthesis?
We employ validated HPLC methods and strict in-process controls. Each batch is tested against a reference standard, and a comprehensive COA is issued, including impurity profiles and residual solvent data.
What are the typical lead times for bulk orders?
For orders up to 100 kg, lead time is typically 2-3 weeks. Larger quantities may require 4-6 weeks, depending on production scheduling. We maintain safety stocks for regular customers.
Can you provide custom synthesis or impurity standards?
Yes, we offer custom synthesis of related impurities or metabolites. Please inquire with our technical team for specific requirements.
What documentation is provided for regulatory support?
We supply COA, SDS, and upon request, technical packages including stability data, residual solvent statements, and GMO/TSE-free declarations.
Sourcing and Technical Support
Selecting the right source for 4-Nitro-2,3-lutidine-N-oxide involves balancing purity, price, and practical handling considerations. From solvent swelling filtration to sub-zero viscosity shifts, our team brings field-tested knowledge to support your procurement and process development. We invite you to leverage our expertise to streamline your supply chain and ensure consistent quality in your Lansoprazole synthesis. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.